Cardiac arrhythmias and hyperkalemia are two dangerous side-effects of haemodialysis. The incidence rate of cardiac arrhythmias in the dialysis patient population ranges from nearly 16% (atrial fibrillation) up to 65% (simple ECG abnormalities).
Hyperkalaemia is common in patients with End-Stage Renal Disease (from 10% to 50%) despite an enhanced adapted gastrointestinal excretion. Profiled potassium Acetate-free Biofiltration (AFB.K™) is a therapeutic approach to cardiac arrhythmias and hyperkalaemia in dialysis patients. It combines the well-known benefits of the AFB™ therapy (particularly for diabetic, cardiopathic, and hypertensive patients) with an independent dialysate potassium profile. The AFB.K™ therapy allows us to set the dialysate potassium high at the beginning of the treatment to avoid electrical disequilibrium of pacemaker cells, and lower during treatment in order to achieve the patient’s personal total body potassium removal.